Tyvaso DPI

Tyvaso DPI is an inhaled dry powder formulation of treprostinil, a prostacyclin mimetic. It is indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3), both to improve exercise ability. Treprostinil acts as a prostacyclin analogue, exerting its effects primarily through direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation. The drug is administered via a handheld dry powder inhaler device, typically four times daily in single-breath doses per cartridge[2][5][7][9]. Tyvaso DPI was approved by the FDA in 2022 for these indications[7].

Brand names

Tyvaso DPI

Other names

treprostinil inhalation powder